GUEST COLUMNISTS

• The Real Cost Of Sites Working Without An Enforceable Agreement: Why Your Site's Quality Of Earnings Is Suspect

  Starting site work before an enforceable agreement may look like flexibility, but it can drain leverage, create unrecoverable costs, and raise financial reporting and GCP concerns.

• The U.S. Clinical Trial Recruiting Pipeline Report – August 2026

  This WhichTrial report breaks down which drug trials are growing the most and the least, drugs that are no longer being studied, and new drugs to the clinic from July and August.

• How VNS-REHAB Aims To Improve Stroke Recovery After Patients Have Plateaued

  Learn how a stroke trial standardized intensive therapy, sustained patient adherence, and exposed access barriers after FDA approval.

• Resensitizing Treatment-Resistant Cancer Holds Promise Over Replacing Once-Efficacious Therapies

  John Yu, MD, of Kairos Pharma, explains why reversing treatment resistance could extend the life of proven cancer therapies and improve patient outcomes.

• Why Oncology Programs Can't Rely On An Inside View Alone

  Discover how looking outside a program can help oncology teams test assumptions, improve feasibility, and make stronger development decisions.

• In Case You Missed Them: Recapping The FDA's Recent Guidances For Cell And Gene Therapies

  I review 10 of the FDA’s guidances spanning the last 12 months, all of which aid cell and gene therapy companies to assure safety and efficacy of these medicines.

• Repurposing Three FDA-Approved Drugs For A New Stroke Recovery Strategy

  When three drugs become one — the polypharmacology strategy, 505(b)(2) pathway, and objective endpoints Nuero-Innovators is relying on to bring new hope to stroke patients.

• Coalition Takes Guesswork Out Of Charcot-Marie-Tooth Disease Research With New Guidance

  A new Charcot-Marie-Tooth guidance introduces practical recommendations to help sponsors design clearer, more patient-centered, regulator-ready trials.